Schizophrenia Trial, Recruiting NCT07616999 Sponsor: The University of Hong Kong Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT07616999
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who took part in a previous clinical trial (registered as NCT00334035) that looked at whether continuing or stopping medication affected the chances of relapse during a first episode of psychosis
  • People who had been diagnosed with schizophrenia or a related psychosis condition (such as schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, or psychosis not otherwise specified) at the time of the original study
  • People who were between 18 and 65 years old when they first joined the original trial
  • People who had been taking antipsychotic medication for at least 12 months before joining the original trial
  • People who had not experienced a return of symptoms (relapse), or who were free of active psychosis symptoms, when they first entered the original trial

Who may not be able to join:

  • People whose psychosis was diagnosed as being caused by drug use
  • People who were being treated with clozapine, mood-stabilising medications (such as lithium, valproate, or carbamazepine), or long-acting injectable (depot) antipsychotic medication
  • People considered to be at high risk of suicide or violence
  • People who were not able to give informed consent when being recruited to the original trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 852-22554486

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
21 May 2026
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Long-term Clinical Outcome

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov